Literature DB >> 33653327

Strategy for mass production of lytic Staphylococcus aureus bacteriophage pSa-3: contribution of multiplicity of infection and response surface methodology.

Sang Guen Kim1, Jun Kwon1, Sib Sankar Giri1, Saekil Yun1, Hyoun Joong Kim1, Sang Wha Kim1, Jung Woo Kang1, Sung Bin Lee1, Won Joon Jung1, Se Chang Park2.   

Abstract

BACKGROUND: Antibiotic-resistant bacteria have emerged as a serious problem; bacteriophages have, therefore, been proposed as a therapeutic alternative to antibiotics. Several authorities, such as pharmacopeia, FDA, have confirmed their safety, and some bacteriophages are commercially available worldwide. The demand for bacteriophages is expected to increase exponentially in the future; hence, there is an urgent need to mass-produce bacteriophages economically. Unlike the replication of non-lytic bacteriophages, lytic bacteriophages are replicated by lysing host bacteria, which leads to the termination of phage production; hence, strategies that can prolong the lysis of host bacteria in bacteria-bacteriophage co-cultures, are required.
RESULTS: In the current study, we manipulated the inoculum concentrations of Staphylococcus aureus and phage pSa-3 (multiplicity of infection, MOI), and their energy sources to delay the bactericidal effect while optimizing phage production. We examined an increasing range of bacterial inoculum concentration (2 × 108 to 2 × 109 CFU/mL) to decrease the lag phase, in combination with a decreasing range of phage inoculum (from MOI 0.01 to 0.00000001) to delay the lysis of the host. Bacterial concentration of 2 × 108 CFU/mL and phage MOI of 0.0001 showed the maximum final phage production rate (1.68 × 1010 plaque forming unit (PFU)/mL). With this combination of phage-bacteria inoculum, we selected glycerol, glycine, and calcium as carbon, nitrogen, and divalent ion sources, respectively, for phage production. After optimization using response surface methodology, the final concentration of the lytic Staphylococcus phage was 8.63 × 1010 ± 9.71 × 109 PFU/mL (5.13-fold increase).
CONCLUSIONS: Therefore, Staphylococcus phage pSa-3 production can be maximized by increasing the bacterial inoculum and reducing the seeding phage MOI, and this combinatorial strategy could decrease the phage production time. Further, we suggest that response surface methodology has the potential for optimizing the mass production of lytic bacteriophages.

Entities:  

Keywords:  Lytic bacteriophage; Mass production; Multiplicity of infection; Optimization; Response surface methodology; Staphylococcus phage

Year:  2021        PMID: 33653327     DOI: 10.1186/s12934-021-01549-8

Source DB:  PubMed          Journal:  Microb Cell Fact        ISSN: 1475-2859            Impact factor:   5.328


  42 in total

1.  FDA approves use of bacteriophages to be added to meat and poultry products.

Authors:  Leslie H Lang
Journal:  Gastroenterology       Date:  2006-11       Impact factor: 22.682

2.  Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control.

Authors:  Richard P Wenzel; Gonzalo Bearman; Michael B Edmond
Journal:  Int J Antimicrob Agents       Date:  2007-06-12       Impact factor: 5.283

Review 3.  Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review.

Authors:  Athanasios Kakasis; Gerasimia Panitsa
Journal:  Int J Antimicrob Agents       Date:  2018-09-17       Impact factor: 5.283

Review 4.  Pulmonary embolism. Part II. Management.

Authors:  M J Tsapogas
Journal:  Ala J Med Sci       Date:  1988-01

Review 5.  Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis.

Authors:  Myrto Eleni Flokas; Spyridon A Karageorgos; Marios Detsis; Michail Alevizakos; Eleftherios Mylonakis
Journal:  Int J Antimicrob Agents       Date:  2017-03-20       Impact factor: 5.283

6.  Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

Authors:  D D Rhoads; R D Wolcott; M A Kuskowski; B M Wolcott; L S Ward; A Sulakvelidze
Journal:  J Wound Care       Date:  2009-06       Impact factor: 2.072

7.  Isolation and characterization of a novel bacteriophage infecting Vibrio alginolyticus.

Authors:  Constantina Kokkari; Elena Sarropoulou; Roberto Bastias; Manolis Mandalakis; Pantelis Katharios
Journal:  Arch Microbiol       Date:  2018-01-25       Impact factor: 2.552

8.  Leukotriene B4, a mediator of inflammation present in synovial fluid in rheumatoid arthritis.

Authors:  E M Davidson; S A Rae; M J Smith
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

9.  Isolation and Genome Characterization of the Virulent Staphylococcus aureus Bacteriophage SA97.

Authors:  Yoonjee Chang; Hakdong Shin; Ju-Hoon Lee; Chul Jong Park; Soon-Young Paik; Sangryeol Ryu
Journal:  Viruses       Date:  2015-10-01       Impact factor: 5.048

10.  Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany.

Authors:  Maia Merabishvili; Daniel De Vos; Gilbert Verbeken; Andrew M Kropinski; Dieter Vandenheuvel; Rob Lavigne; Pierre Wattiau; Jan Mast; Catherine Ragimbeau; Joel Mossong; Jacques Scheres; Nina Chanishvili; Mario Vaneechoutte; Jean-Paul Pirnay
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more
  1 in total

1.  Isolation and characterization of vB_XciM_LucasX, a new jumbo phage that infects Xanthomonas citri and Xanthomonas fuscans.

Authors:  Vinícius Marquioni; Fernando Pacheco Nobre Rossi; Deborah Cezar Mendonça; Layla Farage Martins; Franklin Behlau; João Carlos Setubal; Aline Maria da Silva; Maria Teresa Marques Novo-Mansur
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.